Acquisition, Sale of Hospira Infusion Systems Net Assets, Licensing Arrangement and Collaborative Arrangements - AstraZeneca (Details) - USD ($) $ in Millions			3 Months Ended
		Dec. 22, 2016	Apr. 01, 2018	Jul. 02, 2017	Dec. 31, 2017
Business Acquisition [Line Items]
Goodwill	[1]		$ 56,393		$ 55,952
AstraZeneca [Member]
Business Acquisition [Line Items]
Initial payment		$ 552
Additional payment made for a purchase price adjustment				$ 3
Milestone payment			$ 125	$ 50
Deferred payment		175
Maximum amount of potential milestone payments		75
Maximum amount of potential sales-related payments		$ 600
Term of royalty payments		10 years
Consideration transferred in business acquisition		$ 1,040
Payments for acquisitions, cash portion		555
Contingent consideration assumed		485
Identifiable intangible assets		894
Other current assets		92
Goodwill		73
Deferred tax liabilities		19
In Process Research and Development [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		166
Developed Technology Rights [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		728
Minimum [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Undiscounted royalty payments		250
Maximum [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Undiscounted royalty payments		$ 430

[1] Amounts may not add due to rounding.